Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 6, 2008, Pages 2097-2102

  Wall, Mark J ^a   Chen, Jinsheng ^a   Meegalla, Sanath ^a   Ballentine, Shelley K ^a   Wilson, Kenneth J ^a   DesJarlais, Renee L ^a   Schubert, Carsten ^a   Chaikin, Margery A ^a   Crysler, Carl ^a   Petrounia, Ioanna P ^a   Donatelli, Robert R ^a   Yurkow, Edward J ^a   Boczon, Lisa ^a   Mazzulla, Marie ^a   Player, Mark R ^a   Patch, Raymond J ^a   Manthey, Carl L ^a   Molloy, Christopher ^a   Tomczuk, Bruce ^a   Illig, Carl R ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

2 Quinolones; cFMS; Colony stimulating factor 1 receptor; CSF 1; FMS; M CSF

Indexed keywords

2 QUINOLONE DERIVATIVE; 4 (4 ETHYLPHENYL) 3 (2 METHYL 3H IMIDAZOL 4 YL) 2 QUINOLONE 6 CARBONITRILE; COLONY STIMULATING FACTOR RECEPTOR; MACROPHAGE COLONY STIMULATING FACTOR 1 RECEPTOR KINASE; PHOSPHOTRANSFERASE INHIBITOR; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL PROLIFERATION; FLUORESCENCE POLARIZATION; GENES, FOS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; QUINOLONES; RATS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 40849102934     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.01.088     Document Type: Article

References (19)

1. Sherr C.J. Biochim. Biophys. Acta 948 (1988) 225
2. Moss S.T., and Hamilton J.A. Immunobiology 202 (2000) 18
3. Kluger H.M., Dolled-Filhart M., Rodov S., Kacinski B.M., Camp R.L., and Rimm D.L. Clin. Cancer Res. 10 (2004) 173
4. Lin E.Y., Nguyen A.V., Russell R.G., and Pollard J.W. J. Exp. Med. 193 (2001) 727
5. Yee L.D., and Liu L. Anticancer Res. 20 (2000) 4379
6. Conway J.G., McDonald B., Parham J., Keith B., Rusnak D.W., Shaw E., Jansen M., Lin P., Payne A., Crosby R.M., Johnson J.H., Frick L., Lin M.H., Depee S., Tadepalli S., Votta B., James I., Fuller K., Chambers T.J., Kull F.C., Chamberlain S.D., and Hutchins J.T. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 16078
7. Irvine K.M., Burns C.J., Wilks A.F., Su S., Hume D.A., and Sweet M.J. FASEB J. 20 (2006) 1921
8. Ohno H., Kubo K., Murooka H., Kobayashi Y., Nishitoba T., Shibuya M., Yoneda T., and Isoe T. Mol. Cancer Ther. 5 (2006) 2634
9. Smalley Jr. T.L., Chamberlain S.D., Mills W.Y., Musso D.L., Randhawa S.A., Ray J.A., Samano V., and Frick L. Bioorg. Med. Chem. Lett. 17 (2007) 6257
10. Patch R.J., Brandt B.M., Asgari D., Baindur N., Chadha N.K., Georgiadis T., Cheung W.S., Petrounia I.P., Donatelli R.R., Chaikin M.A., and Player M.R. Bioorg. Med. Chem. Lett. 17 (2007) 6070
11. Schubert C., Schalk-Hihi C., Struble G.T., Ma H.C., Petrounia I.P., Brandt B., Deckman I.C., Patch R.J., Player M.R., Spurlino J.C., and Springer B.A. J. Biol. Chem. 282 (2007) 4094
12. Carver T.E., Bordeau B., Cummings M.D., Petrella E.C., Pucci M.J., Zawadzke L.E., Dougherty B.A., Tredup J.A., Bryson J.W., Yanchunas Jr. J., Doyle M.L., Witmer M.R., Nelen M.I., DesJarlais R.L., Jaeger E.P., Devine H., Asel E.D., Springer B.A., Bone R., Salemme F.R., and Todd M.J. J. Biol. Chem. 280 (2005) 11704
13. 4Tyr. Typical between-run coefficient of variation was less than 30%.
14. Turner J.A. J. Org. Chem. 55 (1990) 4744
15. Nahm S., and Weinreb S.M. Tetrahedron Lett. 22 (1981) 3815
16. Garuti L., Giovanninetti G., Bova S., and Chiarini A. Arch. Pharm. 321 (1988) 377
17. Varchi G., Jensen A.E., Dohle W., Ricci A., Cahiez G., and Knochel P. Synlett (2001) 477
18. Abarbri M., Thibonnet J., Berillon L., Dehmel F., Rottlander M., and Knochel P. J. Org. Chem. 65 (2000) 4618
19. 260. Applied Biosystems, Inc., was the source for the primer probe set for mouse c-fos mRNA (part# Mm00487425) and 18S rRNA (part# 4333760F). Amplification and detection were performed using the ABI Prism 7700 Sequence Detection system with the following profile: 48 °C for 30 min, 95 °C for 10 min and 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Standard curves (six 4-fold dilutions) were created for c-fos mRNA and for 18S rRNA using RNA isolated from one vehicle-treated, CSF-1-induced mouse. Relative expression levels in all other samples were calculated based on the standard curves. c-Fos mRNA values were divided by 18S rRNA values to normalize for total RNA content.